- Latest news▼
-
12:20, July 4 Cell Metabolism: Hot cheeks may be symptom of dangerous disease, researchers find
-
00:38, July 4 Patients with attention-deficit/hyperactivity disorder are left without help
-
00:37, July 3 Innovative way of diagnosing pancreatic cancer is developed
-
10:37, July 2 Mongolia health ministry informs about high risk of bubonic plague in 15 provinces
-
08:41, July 2 Rectal cancer disappeared in all patients in trial of new immunotherapy method, study finds
-
00:51, July 2 Hair started growing in man's throat: Doctors say it's because of smoking
-
20:02, July 1 Russian scientists create fast way to diagnose Alzheimer's disease
-
10:53, July 1 501 cases of measles infection registered in Armenia
-
08:29, July 1 Scientists have developed a monoclonal antibody to fight the deadly Nipah virus
-
11:29, June 28 Kobayashi Pharmaceutical investigating 76 more deaths linked to biologically active supplements
-
08:23, June 28 Children ages 5 to 12 are more likely to get concussions during recreation and other non-sports activities - study
-
18:20, June 27 Depression in adolescents linked to increased risk of cardiovascular disease - study
-
16:38, June 27 Nature Aging: experimental drug rejuvenated the livers of old and sick mice
-
14:55, June 27 Lancet: hypertension may be a major avoidable risk factor for dementia
-
08:43, June 27 Women with heart disease less likely to have concomitant problems corrected during surgery - study
All materials
Rectal cancer disappeared in all patients in trial of new immunotherapy method, study finds
Rectal cancer disappeared in all patients involved in a small clinical trial of a new immunotherapy treatment, according to updated results released in June, reports Euronews.
The study was a collaboration between the US-based Memorial Sloan Kettering Cancer Center (MSK) and the pharmaceutical company GSK.
It looked at a new drug called dostarlimab-gxly to treat patients with a specific type of rectal cancer caused by a genetic mutation.
“As a clinician, I’ve seen firsthand the debilitating impact of standard treatment of dMMR rectal cancer and am thrilled about the potential of dostarlimab-gxly in these patients,” Dr. Andrea Cercek, section head of colorectal cancer from MSK and the study’s principal investigator, said in the statement.
MMRd stands for mismatch repair deficient meaning that the cells have a dysfunctional DNA repair system. These represent around 5 percent of rectal cancers.
The current treatment for such cancer is radiotherapy, chemotherapy, surgery, or a combination of them.
The treatments often have a heavy impact on the patient's quality of life with for example intestinal disorders, bowel incontinence or sexual dysfunctions, according to Dr. Clélia Coutzac, a medical oncologist who was not involved in the study.
“What works very well in these tumours is that we reactivate the system with immunotherapy, and in this case, GSK's dostarlimab, a drug that will guide the lymphocytes to recognise the cancer cells again as harmful and kill them,” Coutzac told Euronews Health.
The patients who followed the six month treatments showed a complete clinical response with “no evidence of tumours” found by MRI, endoscopy or digital exam during the follow-up, according to GSK’s statement.
Coutzac described the results as “amazing”.
Before dostarlimab—also known under its brand name Jemperli—potentially arrives on the market to treat MMRd rectal cancer, further research is needed.
A global study called Azur-1 is designed to further test the efficiency of dostarlimab-gxly when used alone, instead of chemotherapy, radiation, or surgery, and to confirm the MSK findings.
The aforesaid study showed a 100-percent positive response rate in 42 patients with a specific type of rectal cancer who were treated with the experimental immunotherapy.
Follow NEWS.am Medicine on Facebook and Twitter
- Most read
month
week
day
- Nature Aging: experimental drug rejuvenated the livers of old and sick mice 1636
- Depression in adolescents linked to increased risk of cardiovascular disease - study 1617
- Children ages 5 to 12 are more likely to get concussions during recreation and other non-sports activities - study 1422
- Kobayashi Pharmaceutical investigating 76 more deaths linked to biologically active supplements 1422
- Hair started growing in man's throat: Doctors say it's because of smoking 813
- Russian scientists create fast way to diagnose Alzheimer's disease 806
- Scientists have developed a monoclonal antibody to fight the deadly Nipah virus 786
- 501 cases of measles infection registered in Armenia 768
- Rectal cancer disappeared in all patients in trial of new immunotherapy method, study finds 686
- Mongolia health ministry informs about high risk of bubonic plague in 15 provinces 610
- Innovative way of diagnosing pancreatic cancer is developed 436
- Patients with attention-deficit/hyperactivity disorder are left without help 143
- Cell Metabolism: Hot cheeks may be symptom of dangerous disease, researchers find 133
- Find us on Facebook
- Poll